Pulmonary valve disorder
Also known as: Respiratory, Respiration, Pulmonary, Breath
Methodology & AI Transparency ⓘ
Pulmonary valve disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Heart & Cardiovascular Disease practice, Pulmonary valve disorder (also termed Respiratory or Respiration) (ICD-10 I37.9) is stratified through 12-lead resting electrocardiography [Pulmonary valve disorder I37.9], pairing targeted symptom control with longitudinal High-Sensitivity Troponin I [Pulmonary valve disorder I37.9] surveillance.
- 2 Real-world patient consensus: Synonyms for Pulmonary valve disorder (I37.9): Respiratory, Respiration, Pulmonary (Heart & Vascular).
- 3 Typical cash cost range: Clinicians assessing Pulmonary valve disorder focus on myocardial oxygen supply-demand in Pulmonary valve disorder (I37.9: mismatch) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Pulmonary valve disorder: NT-proBNP [Pulmonary valve disorder I37.9] (< 100 pg/mL (I37.9)) and High-Sensitivity Troponin I [Pulmonary valve disorder I37.9].
Ask our AI Specialists anything about Pulmonary valve disorder
What Is Pulmonary valve disorder?
Within Heart & Cardiovascular Disease practice, Pulmonary valve disorder (also termed Respiratory or Respiration) (ICD-10 I37.9) is stratified through 12-lead resting electrocardiography [Pulmonary valve disorder I37.9], pairing targeted symptom control with longitudinal High-Sensitivity Troponin I [Pulmonary valve disorder I37.9] surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Pulmonary valve disorder (ICD-10 I37.9) is driven by myocardial oxygen supply-demand in Pulmonary valve disorder (I37.9: mismatch); specialists in Heart & Cardiovascular Disease monitor High-Sensitivity Troponin I [Pulmonary valve disorder I37.9] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Pulmonary valve disorder (I37.9): palpitations, skipped beats, in Pulmonary valve disorder (I37.9: or irregular resting)
- • Secondary Pulmonary valve disorder clinical sign: unexplained lower-extremity ankle in Pulmonary valve disorder (I37.9: edema or rapid)
- • Symptom flares in Pulmonary valve disorder correlating with NT-proBNP [Pulmonary valve disorder I37.9] deviation outside < 100 pg/mL (I37.9)
- • Functional heart & vascular impact requiring 12-lead resting electrocardiography [Pulmonary valve disorder I37.9] evaluation (I37.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pulmonary valve disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I37.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: NT-proBNP [Pulmonary valve disorder I37.9] | < 100 pg/mL (I37.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Pulmonary valve disorder I37.9] | < 14 ng/L (I37.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Pulmonary valve disorder I37.9] | < 70 mg/dL (I37.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pulmonary valve disorder
Treatment selection for Pulmonary valve disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pulmonary valve disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| New Insights on Relationship Between Time From Diagnosis and Morbidity/Mortality in lung Arterial: What a 1,156-Participant Study Found In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. Chest • 2021-07-15 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 33545163 ↗ |
| New Insights on Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic: What a 975-Participant Study Found Ensifentrine produced clinically meaningful improvements in multiple dyspnea measures in patients with symptomatic, moderate-to-severe COPD. Expert review of respiratory medicine • 2024-08-15 • Phase III Randomized Trial | N = 975 | 93/100 | PMID 39106052 ↗ |
| What the Latest Evidence Really Says About Vasodilators for persistent lung high blood pressure of the newborn: A network Milrinone, Sildenafil, and Sildenafil_Milrinone reduced the mortality of neonates with PPHN. Pediatric pulmonology • 2024-12-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 39193897 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of melatonin administration on subjective sleep quality in chronic We conclude that melatonin can improve sleep in COPD. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas • 2008-10-15 • Randomized Controlled Trial | N = 12 | 88/100 | PMID 19030713 ↗ |
Pulmonary valve disorder Patient Community & “People Like Me” Threads
Filter Pulmonary valve disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.